NCT06859684
- Conditions
- Adenocarcinoma, Carcinoma, Cholangiocarcinoma, +7 more
- Locations
-
- West China Hospital, Sichuan University Chengdu, Sichuan, China
Clinical trial condition
Durvalumab
Explore clinical trials studying Durvalumab. Study availability and eligibility vary by location and protocol.
5 public trials
3 recruiting studies
Durvalumab trial results
NCT06999694
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more
- Locations
-
- Chang Gung Memorial Hospital at Linkou Taoyuan City, Taiwan
NCT06999707
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more
- Locations
-
- Chang Gung Memorial Hospital at Linkou Taoyuan City, Taiwan
Enrolling by Invitation
Evaluation of Efficacy and Safety of Immune Check Point Inhibitors in Hepatocellular Carcinoma Patients in Ain Shams University Hospitals
NCT07088081
- Conditions
- Adenocarcinoma, Atezolizumab and Bevacizumab in Hepatocellular Carcinoma, Carcinoma, +14 more
- Locations
-
- Ain Shams University Cairo, Abbasya, Egypt
Active, Not Recruiting
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
NCT05092412
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Durvalumab, +10 more
- Locations
-
- Chongqing University Cancer Hospital Chongqing, Chongqing Municipality, China
- Henan Provincial People's Hospital Zhengzhou, Henan, China
- West China Hospital Sichuan University Chengdu, Sichuan, China